氯尼达明治疗转移性乳腺癌的II期研究。
Phase II study of lonidamine in metastatic breast cancer.
作者信息
Pronzato P, Amoroso D, Bertelli G, Conte P F, Cusimano M P, Ciottoli G B, Gulisano M, Lionetto R, Rosso R
机构信息
Istituto Nazionale per la Ricerca sul Cancro, Divisione di Oncologia Medica, Genova, Italy.
出版信息
Br J Cancer. 1989 Feb;59(2):251-3. doi: 10.1038/bjc.1989.51.
Abstract
Thirty patients with previously treated metastatic breast cancer were entered in a phase II study with oral lonidamine. Twenty-eight patients are evaluable for toxicity and 25 for response. A partial remission was obtained in four patients (16%) and disease stability in 11 (44%): 10 patients progressed (40%). Toxicity was acceptable, consisting mainly of myalgias (39% of patients) and asthenia (21.4%). No myelotoxicity was observed. The drug is active in previously treated metastatic breast cancer and, because of its peculiar pattern of action and toxicity, deserves to be evaluated in combination with cytotoxic chemotherapy.
摘要
30例先前接受过治疗的转移性乳腺癌患者进入了一项口服氯尼达明的II期研究。28例患者可评估毒性，25例可评估疗效。4例患者（16%）获得部分缓解，11例患者（44%）病情稳定，10例患者（40%）病情进展。毒性反应可接受，主要包括肌痛（39%的患者）和乏力（21.4%）。未观察到骨髓毒性。该药物在先前接受过治疗的转移性乳腺癌中具有活性，由于其独特的作用方式和毒性，值得与细胞毒性化疗联合进行评估。
相似文献
1
Phase II study of lonidamine in metastatic breast cancer.氯尼达明治疗转移性乳腺癌的II期研究。
Br J Cancer. 1989 Feb;59(2):251-3. doi: 10.1038/bjc.1989.51.
2
3
Lonidamine in advanced colorectal cancer: a phase II study of the Italian Oncology Group for Clinical Research (GOIRC).氯尼达明治疗晚期结直肠癌：意大利临床研究肿瘤学组（GOIRC）的一项II期研究。
Tumori. 1989 Jun 30;75(3):277-9. doi: 10.1177/030089168907500318.
4
Phase II study of Lonidamine in cancer patients.氯尼达明在癌症患者中的II期研究。
Oncology. 1984;41 Suppl 1:66-8. doi: 10.1159/000225889.
5
Phase II study of lonidamine in patients with metastatic breast cancer. An Eastern Cooperative Oncology Group study.氯尼达明治疗转移性乳腺癌患者的II期研究。一项东部肿瘤协作组的研究。
Invest New Drugs. 1990 Nov;8(4):397-9. doi: 10.1007/BF00198600.
6
Phase I toxicologic study of Lonidamine in cancer patients.氯尼达明在癌症患者中的I期毒理学研究。
Oncology. 1984;41 Suppl 1:56-9. doi: 10.1159/000225887.
7
Lonidamine in metastatic breast cancer.氯尼达明治疗转移性乳腺癌
Semin Oncol. 1991 Apr;18(2 Suppl 4):62-5.
8
Phase II study of lonidamine in inoperable non-small-cell lung cancer.氯尼达明治疗不可切除非小细胞肺癌的II期研究。
Oncology. 1984;41 Suppl 1:86-9. doi: 10.1159/000225893.
9
A phase II clinical and pharmacokinetic study of Lonidamine in patients with advanced breast cancer.氯尼达明治疗晚期乳腺癌患者的II期临床及药代动力学研究。
Br J Cancer. 1991 Sep;64(3):593-7. doi: 10.1038/bjc.1991.356.
引用本文的文献
1
Towards an Integral Therapeutic Protocol for Breast Cancer Based upon the New H-Centered Anticancer Paradigm of the Late Post-Warburg Era.基于后沃伯格时代的新以 H 为中心的抗癌范式的乳腺癌整体治疗方案。
Int J Mol Sci. 2020 Oct 10;21(20):7475. doi: 10.3390/ijms21207475.
2
A New and Integral Approach to the Etiopathogenesis and Treatment of Breast Cancer Based upon Its Hydrogen Ion Dynamics.基于氢离子动力学的乳腺癌病因发生学和治疗的全新整体方法
Int J Mol Sci. 2020 Feb 7;21(3):1110. doi: 10.3390/ijms21031110.
3
The 18-kDa translocator protein (TSPO) disrupts mammary epithelial morphogenesis and promotes breast cancer cell migration.18kDa 转位蛋白（TSPO）破坏乳腺上皮形态发生并促进乳腺癌细胞迁移。
PLoS One. 2013 Aug 14;8(8):e71258. doi: 10.1371/journal.pone.0071258. eCollection 2013.
4
Relative cytotoxicities of adriamycin and epirubicin in combination with lonidamine against human bladder cancer cell lines.阿霉素和表柔比星联合氯尼达明对人膀胱癌细胞系的相对细胞毒性。
Urol Res. 1995;22(6):367-72. doi: 10.1007/BF00296877.
5
Phase II study of high-dose epirubicin, lonidamine, alpha 2b interferon in advanced breast cancer.高剂量表柔比星、氯尼达明、α2b干扰素治疗晚期乳腺癌的II期研究。
Breast Cancer Res Treat. 1995 Sep;35(3):243-8. doi: 10.1007/BF00665975.
6
A phase II clinical and pharmacokinetic study of Lonidamine in patients with advanced breast cancer.氯尼达明治疗晚期乳腺癌患者的II期临床及药代动力学研究。
Br J Cancer. 1991 Sep;64(3):593-7. doi: 10.1038/bjc.1991.356.
7
Reversal of adriamycin resistance by lonidamine in a human breast cancer cell line.氯尼达明对人乳腺癌细胞系阿霉素耐药性的逆转作用
Br J Cancer. 1991 Sep;64(3):534-6. doi: 10.1038/bjc.1991.345.
本文引用的文献
1
Reporting results of cancer treatment.癌症治疗结果报告。
Cancer. 1981 Jan 1;47(1):207-14. doi: 10.1002/1097-0142(19810101)47:1<207::aid-cncr2820470134>3.0.co;2-6.
2
Effects of lonidamine alone or combined with hyperthermia in some experimental cell and tumour systems.氯尼达明单独或与热疗联合在某些实验性细胞和肿瘤系统中的作用。
Br J Cancer. 1983 Feb;47(2):221-31. doi: 10.1038/bjc.1983.30.
3
Lonidamine and radiotherapy in head and neck cancers. A pilot study.氯尼达明与头颈癌放疗：一项初步研究
Oncology. 1984;41 Suppl 1:113-5. doi: 10.1159/000225898.
4
Lonidamine plus adriamycin versus adriamycin alone in the adjuvant treatment of recurrent papillary carcinomas of the urinary bladder.氯尼达明联合阿霉素与单纯阿霉素用于复发性膀胱乳头状癌辅助治疗的比较
Oncology. 1984;41 Suppl 1:104-7. doi: 10.1159/000225896.
5
Lonidamine alone and in combination with other chemotherapeutic agents in the treatment of cancer patients.氯尼达明单独及与其他化疗药物联合用于癌症患者的治疗。
Oncology. 1984;41 Suppl 1:108-12. doi: 10.1159/000225897.
6
Inhibition of the recovery from potentially lethal damage by lonidamine.氯尼达明对潜在致死性损伤恢复的抑制作用。
Br J Cancer. 1984 Nov;50(5):657-60. doi: 10.1038/bjc.1984.232.
7
In vitro and in vivo potentiation by lonidamine of the antitumor effect of adriamycin.氯尼达明对阿霉素抗肿瘤作用的体内外增效作用。
Anticancer Res. 1986 Sep-Oct;6(5):1245-9.
8
Potentiation of adriamycin cytotoxicity in P388 murine leukemia sensitive and resistant to adriamycin by use of lonidamine and hyperthermia.通过使用氯尼达明和热疗增强阿霉素对P388小鼠白血病敏感株和耐药株的细胞毒性。
Tumori. 1986 Oct 31;72(5):469-73. doi: 10.1177/030089168607200503.
9
10
Enhancing effect of lonidamine on the inhibition of mitochondrial respiration by adriamycin.氯尼达明对阿霉素抑制线粒体呼吸的增强作用。
Anticancer Res. 1987 Jul-Aug;7(4B):799-802.
Zotero 插件